LLY
Eli Lilly and Company
LLY has the edge over NMTC overall, supported by stronger fundamentals and lower modeled downside.
NMTC
NeuroOne Medical Technologies Corporation
NMTC's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NMTC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
NMTC's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NMTC PE Valuation
NMTC has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NMTC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect NMTC's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NMTC on earnings quality, reporting a profit while its opponent remains loss making.
NMTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.04 | -$0.14 |
| Q1 2026 | -$0.94 | +$0.38 |
| Q4 2025 | -$1.08 | +$0.48 |
| Q3 2025 | -$0.54 | +$2.22 |
| Q2 2025 | -$0.90 | +$1.98 |
| Q1 2025 | -$1.32 | +$2.16 |
| Q4 2024 | -$1.56 | +$2.52 |
| Q3 2024 | -$2.76 | +$1.14 |
NMTC is still losing money, but far less than before: $1.04 per share over the past year, against $17.46 at its worst in mid-2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NMTC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NMTC on profitability, with a higher operating margin.
NMTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2M | +16% |
| Q1 2026 | $1.9M | +34% |
| Q4 2025 | $2.9M | -12% |
| Q3 2025 | $2.7M | +907% |
| Q2 2025 | $1.7M | +105% |
| Q1 2025 | $1.4M | +0.7% |
| Q4 2024 | $3.3M | +235% |
| Q3 2024 | $272.3K | -63% |
NMTC's revenue is recovering but still below its 2024 peak: $2M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -123% | -12 points |
| Q1 2026 | -129% | +65 points |
| Q4 2025 | -59% | -111 points |
| Q3 2025 | -50% | +985 points |
| Q2 2025 | -111% | +227 points |
| Q1 2025 | -193% | +16 points |
| Q4 2024 | 52% | +399 points |
| Q3 2024 | -1034% | -608 points |
NMTC's operating margin was −123% last quarter, down 12 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with NMTC at up 8.9%.
NMTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.4M | -$1.3M |
| Q4 2025 | -$3.2M | -1617% |
| Q3 2025 | -$1.5M | +$1.2M |
| Q1 2025 | -$56.1K | +$2.2M |
| Q4 2024 | $208K | +$4.1M |
| Q3 2024 | -$2.7M | +$256.7K |
| Q2 2024 | -$2.4M | +$704.3K |
| Q1 2024 | -$2.2M | +$1.5M |
NMTC has burned cash in almost every quarter: −$7M over the past year, against −$5M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NMTC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NMTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +255K shares |
| 1 year | +69% | +3.6M shares |
| 3 years | +223% | +6M shares |
| 5 years | +868% | +7.8M shares |
| Available history | +1227% | +8.1M shares |
NMTC has 9M diluted shares, up 69% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NMTC Net Leverage
NMTC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NMTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.9 | Oversold |
| Stochastic | 3.3 | Oversold |
NMTC's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NMTC PE vs Healthcare Sector
NMTC has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NMTC on trend strength, trading above more of its moving averages.
NMTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.00 | 25% below |
| 20 week MA | $1.59 | 53% below |
| 50 week MA | $3.28 | 77% below |
| 100 week MA | $4.09 | 82% below |
| 200 week MA | $5.51 | 86% below |
NMTC is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NMTC on returns for 2026, with the stronger performance.
NMTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.7 | $27.5 | -32% |
| 2021 | $27.5 | $13.2 | -52% |
| 2022 | $13.2 | $9.24 | -30% |
| 2023 | $9.24 | $9.48 | +2.6% |
| 2024 | $9.48 | $4.91 | -48% |
| 2025 | $4.91 | $4.38 | -11% |
| 2026 YTD | $4.38 | $0.75 | -83% |
NMTC has finished lower in five of the last six years. It's down 83% so far in 2026.